SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending sharply lower after a proposed near-flat Medicare Advantage payment rate for 2027, amplifying concerns about future revenue despite beating recent earnings. This regulatory hit is driving widespread discussion, with many investors debating whether it's an overreaction creating a 'buy the dip' opportunity or a significant re-rating of the managed care sector's outlook.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune (ALT) is a trending topic amidst strong community debate, largely driven by its FDA Breakthrough Therapy Designation for pemvidutide in MASH, which bulls view as a significant derisking event. Speculation around an imminent acquisition or major partnership from big pharma players in the highly active metabolic disease sector is rampant, with investors keenly watching if the stock can decisively break key resistance levels. However, some continue to voice concerns over past trial data and management actions, leading to a polarized discussion.

Richtech Robotics, Inc. engages in the development of robotics and artificial intelligence. The firm designs, manufactures, and sells robots to restaurants, hotels, senior living centers, casinos, factories, and movie theaters. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company was founded by Zhen Wu Huang and Zhen Qiang Huang on July 19, 2016 and is headquartered in Las Vegas, NV.

Richtech Robotics Inc. - Ordinary Shares - Class B

Richtech Robotics Inc.

Richtech Robotics (RR) is trending following its announced collaboration with Microsoft, integrating Azure AI into its ADAM robots for advanced agentic AI capabilities. This partnership is seen by the community as a significant validation, fueling excitement for long-term growth within the burgeoning robotics and AI sector, especially amid discussions around high short interest and potential for a squeeze.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as the FDA lifted the clinical hold on its MAGNITUDE-2 Phase 3 trial, complemented by recent positive data for its hereditary angioedema treatment. This news has sparked community excitement, driving discussions around the stock's high short interest and potential for a significant rebound. Many view these developments as a strong positive for the broader gene-editing sector, with some noting consistent institutional buying despite past volatility.

Pinterest, Inc. engages in the operation of a pinboard-style photo-sharing website. It allows users to create and manage theme-based image collections such as events, interests, and hobbies. The company was founded by Benjamin Silbermann, Paul C. Sciarra, and Evan Sharp in October 2008 and is headquartered in San Francisco, CA.

Pinterest Inc - Ordinary Shares - Class A

Pinterest Inc

Pinterest is trending following its announcement of a global restructuring plan, including workforce reductions and a strategic pivot towards AI initiatives, which has led to a notable stock decline. The market reaction is split, with some viewing the significant drop as an overreaction given the company's financials, while others are questioning its competitive position and actively discussing potential acquisition scenarios, including recent rumors involving OpenAI. Many investors emphasize the company's perceived undervaluation, strong cash flow, and lack of debt amidst a challenging advertising landscape and intense market competition.

Virtuix Holdings Inc. - Ordinary Shares - Class A

Virtuix Holdings Inc. (VTIX) is generating significant buzz as it begins trading on Nasdaq, exciting long-term shareholders and drawing new interest. The community is actively discussing its debut, particularly noting its connection to the booming AI and gaming sectors. Investors are closely watching its initial market performance and impressive reported revenue growth.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is trending following a substantial U.S. government investment, including a significant loan and equity stake, aimed at bolstering the domestic rare earth supply chain. The community is buzzing with bullish sentiment, anticipating a major upside akin to other government-backed entities, despite immediate frustrations over perceived price manipulation and shorting efforts. Many view current price action as an opportunity to accumulate, driven by national security implications and critical mineral demand.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

CVS Health is trending following news of proposed minimal Medicare Advantage payment rate increases for an upcoming year, which is impacting the broader health insurance sector and causing significant downward pressure on its stock. Investors are actively debating whether the steep decline presents a "buy the dip" opportunity for long-term holders, given the company's diversified model, while others remain cautious due to potential margin pressure and regulatory uncertainty across managed care.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending due to intense controversy surrounding recent federal immigration enforcement actions, which have sparked widespread public and political debate. Supporters view these operations as vital for national security, while critics denounce them as governmental overreach and unconstitutional. This highly polarized discussion is driving significant social media engagement and market conversation around the stock, reflecting broader implications for policy and public sentiment.

BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Ness Ziona, Israel.

BiomX Inc

BiomX Inc. (PHGE) is experiencing significant trading activity and price surges after a recent 13D filing revealed Pyu Pyu Capital's 19.99% stake. The community is sharply divided, with many speculating on a potential short squeeze fueled by the company's low float, while others express caution regarding the rally's sustainability amidst past dilution and clinical setbacks. As a clinical-stage biotech, conversation centers on whether current momentum reflects genuine pipeline progress or a speculative, short-term move.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lam Research setting up for a Q2 beat — is this the entry point? 🔥

$LRCX’s Q2 results are likely to reflect benefits from strong demand for AI chips and rising DRAM spending, a powerful combo supporting earnings momentum.

Is the stock worth buying ahead of the print? Full take here 👉  https://www.zacks.com/stock/news/2822185/lrcx-likely-to-beat-q2-earnings-estimates-should-you-buy-the-stock?cid=sm-stocktwits-2-2822185-teaser-30287&amp;ADID=SYND_STOCKTWITS_TWEET_2_2822185_TEASER_30287

Zacks

Pardon Our Interruption

Zacks Research

Lam Research Corp.

Lam Research setting up for a Q2 beat — is this the entry point? 🔥



’s Q2 results are likely to reflect benefits from strong demand for AI chips and rising DRAM spending, a powerful combo supporting earnings momentum.

Is the stock worth buying ahead of the print? Full take here 👉  

This account is recognized as an Official Stocktwits Research Partner — working in close collaboration with Stocktwits to deliver in-depth research and market analysis.